Logo image of AXGN

AXOGEN INC (AXGN) Stock Fundamental Analysis

NASDAQ:AXGN - Nasdaq - US05463X1063 - Common Stock - Currency: USD

10.93  -0.13 (-1.18%)

After market: 10.93 0 (0%)

Fundamental Rating

4

Taking everything into account, AXGN scores 4 out of 10 in our fundamental rating. AXGN was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While AXGN seems to be doing ok healthwise, there are quite some concerns on its profitability. AXGN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

AXGN had positive earnings in the past year.
AXGN had a positive operating cash flow in the past year.
In the past 5 years AXGN always reported negative net income.
AXGN had negative operating cash flow in 4 of the past 5 years.
AXGN Yearly Net Income VS EBIT VS OCF VS FCFAXGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

With a decent Return On Assets value of -3.65%, AXGN is doing good in the industry, outperforming 67.38% of the companies in the same industry.
AXGN has a better Return On Equity (-6.80%) than 70.05% of its industry peers.
Industry RankSector Rank
ROA -3.65%
ROE -6.8%
ROIC N/A
ROA(3y)-10.24%
ROA(5y)-11.1%
ROE(3y)-20.3%
ROE(5y)-20.84%
ROIC(3y)N/A
ROIC(5y)N/A
AXGN Yearly ROA, ROE, ROICAXGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Gross Margin of AXGN (74.18%) is better than 86.63% of its industry peers.
In the last couple of years the Gross Margin of AXGN has remained more or less at the same level.
AXGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-1.5%
AXGN Yearly Profit, Operating, Gross MarginsAXGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

5

2. Health

2.1 Basic Checks

AXGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AXGN has more shares outstanding
Compared to 5 years ago, AXGN has more shares outstanding
The debt/assets ratio for AXGN has been reduced compared to a year ago.
AXGN Yearly Shares OutstandingAXGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AXGN Yearly Total Debt VS Total AssetsAXGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

AXGN has an Altman-Z score of 2.64. This is not the best score and indicates that AXGN is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.64, AXGN is doing good in the industry, outperforming 64.71% of the companies in the same industry.
A Debt/Equity ratio of 0.45 indicates that AXGN is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.45, AXGN is in line with its industry, outperforming 43.85% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Altman-Z 2.64
ROIC/WACCN/A
WACC9.23%
AXGN Yearly LT Debt VS Equity VS FCFAXGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

AXGN has a Current Ratio of 4.28. This indicates that AXGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.28, AXGN is in the better half of the industry, outperforming 67.38% of the companies in the same industry.
AXGN has a Quick Ratio of 2.65. This indicates that AXGN is financially healthy and has no problem in meeting its short term obligations.
AXGN has a Quick ratio (2.65) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.28
Quick Ratio 2.65
AXGN Yearly Current Assets VS Current LiabilitesAXGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

AXGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 221.43%, which is quite impressive.
AXGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.81%.
Measured over the past years, AXGN shows a quite strong growth in Revenue. The Revenue has been growing by 11.92% on average per year.
EPS 1Y (TTM)221.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)18.81%
Revenue growth 3Y13.72%
Revenue growth 5Y11.92%
Sales Q2Q%17.36%

3.2 Future

AXGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.46% yearly.
AXGN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.96% yearly.
EPS Next Y63.46%
EPS Next 2Y93.05%
EPS Next 3Y76.15%
EPS Next 5Y45.46%
Revenue Next Year16.29%
Revenue Next 2Y16.22%
Revenue Next 3Y16.51%
Revenue Next 5Y15.96%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AXGN Yearly Revenue VS EstimatesAXGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
AXGN Yearly EPS VS EstimatesAXGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 64.29, AXGN can be considered very expensive at the moment.
AXGN's Price/Earnings ratio is a bit cheaper when compared to the industry. AXGN is cheaper than 67.38% of the companies in the same industry.
AXGN is valuated expensively when we compare the Price/Earnings ratio to 27.45, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 22.56, AXGN is valued on the expensive side.
AXGN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AXGN is cheaper than 76.47% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.90. AXGN is around the same levels.
Industry RankSector Rank
PE 64.29
Fwd PE 22.56
AXGN Price Earnings VS Forward Price EarningsAXGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AXGN is valued a bit cheaper than 63.10% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 70.67
AXGN Per share dataAXGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as AXGN's earnings are expected to grow with 76.15% in the coming years.
PEG (NY)1.01
PEG (5Y)N/A
EPS Next 2Y93.05%
EPS Next 3Y76.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AXGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AXOGEN INC

NASDAQ:AXGN (7/3/2025, 7:03:38 PM)

After market: 10.93 0 (0%)

10.93

-0.13 (-1.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners86.36%
Inst Owner Change8.68%
Ins Owners0.95%
Ins Owner Change-0.36%
Market Cap497.75M
Analysts84.29
Price Target24.74 (126.35%)
Short Float %5.23%
Short Ratio3.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-54.04%
Min EPS beat(2)-222.55%
Max EPS beat(2)114.46%
EPS beat(4)3
Avg EPS beat(4)308.39%
Min EPS beat(4)-222.55%
Max EPS beat(4)1125.49%
EPS beat(8)7
Avg EPS beat(8)184.9%
EPS beat(12)11
Avg EPS beat(12)144.75%
EPS beat(16)14
Avg EPS beat(16)113.52%
Revenue beat(2)0
Avg Revenue beat(2)-0.88%
Min Revenue beat(2)-1.48%
Max Revenue beat(2)-0.28%
Revenue beat(4)2
Avg Revenue beat(4)1.96%
Min Revenue beat(4)-1.48%
Max Revenue beat(4)8.25%
Revenue beat(8)4
Avg Revenue beat(8)0.16%
Revenue beat(12)6
Avg Revenue beat(12)0.06%
Revenue beat(16)7
Avg Revenue beat(16)-0.74%
PT rev (1m)-7.18%
PT rev (3m)-7.18%
EPS NQ rev (1m)3.45%
EPS NQ rev (3m)-25%
EPS NY rev (1m)-2.34%
EPS NY rev (3m)-25.6%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)-0.79%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-0.11%
Valuation
Industry RankSector Rank
PE 64.29
Fwd PE 22.56
P/S 2.56
P/FCF N/A
P/OCF 137.42
P/B 4.72
P/tB 5
EV/EBITDA 70.67
EPS(TTM)0.17
EY1.56%
EPS(NY)0.48
Fwd EY4.43%
FCF(TTM)0
FCFYN/A
OCF(TTM)0.08
OCFY0.73%
SpS4.27
BVpS2.31
TBVpS2.18
PEG (NY)1.01
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.65%
ROE -6.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.18%
FCFM N/A
ROA(3y)-10.24%
ROA(5y)-11.1%
ROE(3y)-20.3%
ROE(5y)-20.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-1.5%
F-Score6
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Debt/EBITDA 6.42
Cap/Depr 49.14%
Cap/Sales 1.98%
Interest Coverage N/A
Cash Conversion 48.72%
Profit Quality N/A
Current Ratio 4.28
Quick Ratio 2.65
Altman-Z 2.64
F-Score6
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)337.29%
Cap/Depr(5y)669.18%
Cap/Sales(3y)9.04%
Cap/Sales(5y)13.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)221.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y63.46%
EPS Next 2Y93.05%
EPS Next 3Y76.15%
EPS Next 5Y45.46%
Revenue 1Y (TTM)18.81%
Revenue growth 3Y13.72%
Revenue growth 5Y11.92%
Sales Q2Q%17.36%
Revenue Next Year16.29%
Revenue Next 2Y16.22%
Revenue Next 3Y16.51%
Revenue Next 5Y15.96%
EBIT growth 1Y97.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1538.76%
EBIT Next 3Y212.61%
EBIT Next 5YN/A
FCF growth 1Y99.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y129.12%
OCF growth 3YN/A
OCF growth 5YN/A